Want to see AU:EMV full AI Analyst Report?
EMV Stock Chart & Stats
AU$1.72
AU$0.06(3.90%)
At close: 4:00 PM EDT
AU$1.72
AU$0.06(3.90%)
Day’s Range― - ―
52-Week RangeAU$1.47 - AU$2.43
Previous CloseN/A
Volume21.03K
Average Volume (3M)31.57K
Market Cap
AU$163.14M
Enterprise ValueAU$127.13
Total Cash (Recent Filing)AU$17.10M
Total Debt (Recent Filing)AU$3.41M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding92,955,560
10 Day Avg. Volume41,010
30 Day Avg. Volume31,574
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)8.78
Price to Sales (P/S)0.00
P/FCF Ratio-21.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside83.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.11
Revenue Forecast (FY)AU$5.00M
Bulls Say, Bears Say
Bulls Say
Portable Point-of-care ImagingA portable system designed for point-of-care use could address workflow limitations of conventional brain imaging, supporting faster clinical decisions and broadening access across ambulances, emergency departments, and bedside settings if development and validation succeed.
Broad Neurological Use CaseTargeting both stroke and other neurological conditions gives the platform a potentially broader clinical application than a single-disease device. This may improve the addressable market and create future expansion opportunities if clinical utility is established.
Moderate LeverageModerate leverage limits dependence on debt financing and reduces balance-sheet pressure while the company develops its technology. The improved debt-to-equity position and meaningful equity base provide some flexibility to fund operations and milestones.
Bears Say
Revenue DisruptionThe collapse to zero revenue indicates that the prior revenue base was not yet durable or that commercialization has been disrupted. Until recurring sales are demonstrated, forecasting growth, validating demand, and funding operations remain difficult.
Persistent Operating LossesRecurring losses across the provided history show that the business has not yet converted its technology into sustainable economics. Continued negative margins can constrain reinvestment capacity and increase reliance on external funding while commercialization remains unproven.
Worsening Cash BurnPersistent and worsening free cash flow consumption raises the company’s funding needs and creates execution risk around development and commercialization milestones. Even with moderate leverage, ongoing cash outflows may require additional capital before self-funding is achieved.
EMvision Medical Devices Ltd. News
EMV FAQ
What was EMvision Medical Devices Ltd.’s price range in the past 12 months?
EMvision Medical Devices Ltd. lowest share price was AU$1.47 and its highest was AU$2.43 in the past 12 months.
What is EMvision Medical Devices Ltd.’s market cap?
EMvision Medical Devices Ltd.’s market cap is AU$163.14M.
When is EMvision Medical Devices Ltd.’s upcoming earnings report date?
EMvision Medical Devices Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 173 days.
How were EMvision Medical Devices Ltd.’s earnings last quarter?
EMvision Medical Devices Ltd. released its earnings results on Aug 23, 2026. The company reported -AU$0.047 earnings per share for the quarter.
Is EMvision Medical Devices Ltd. overvalued?
According to Wall Street analysts EMvision Medical Devices Ltd.’s price is currently Undervalued.
Does EMvision Medical Devices Ltd. pay dividends?
EMvision Medical Devices Ltd. does not currently pay dividends.
What is EMvision Medical Devices Ltd.’s EPS estimate?
EMvision Medical Devices Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EMvision Medical Devices Ltd. have?
EMvision Medical Devices Ltd. has 92,955,560 shares outstanding.
What happened to EMvision Medical Devices Ltd.’s price movement after its last earnings report?
EMvision Medical Devices Ltd. reported an EPS of -AU$0.047 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EMvision Medical Devices Ltd.?
Currently, no hedge funds are holding shares in AU:EMV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EMvision Medical Devices Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.15 (83.14% Upside)
AU$3.15 (83.14% Upside)
Blogger Sentiment
Bullish
AU:EMV Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
47.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
EMvision Medical Devices Ltd.
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile brain scanner engineered for the swift detection and continuous tracking of strokes, in addition to fulfilling other medical imaging necessities. Founded in 2017, its operations are headquartered in Macquarie Park.
EMV Stock 12 Month Forecast
Average Price Target
AU$3.15
▲(83.14% Upside)
Technical Analysis
Compumedics Limited
―
Neurotech International
―
Cyclopharm Limited
―
Control Bionics Ltd.
―
4DMedical Ltd
―